Mechanism of ActionBaricitinib is an immunomodulatory drug classified as a Janus kinase (JAK) inhibitor. Its active ingredient suppresses excessive im···【Read More】
Update: 2026-03-12Source: Haiou HealthViews: 165
Strict ContraindicationsThe following groups must not use this medication under any circumstances:Patients with a known hypersensitivity to any compon···【Read More】
Update: 2026-03-12Source: Haiou HealthViews: 157
Mechanism of ActionLenvatinib is a targeted anticancer drug that exerts antitumor effects by blocking the activity of specific proteins. It primarily ···【Read More】
Update: 2026-03-12Source: Haiou HealthViews: 160
Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that typically manifests in early childhood. Its severity varies greatly and can reduc···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 193
The U.S. Food and Drug Administration (FDA) approved on September 10 the oral selective MEK inhibitor Koselugo (selumetinib) in oral granule and capsu···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 180
On November 19, 2025, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved its mitogen-activated protein kinase kinase ···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 178
The price of giretinib (generic name: giretinib tablets) varies depending on the region, specification, medical insurance policy, and purchase channel···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 181
Gilteritinib is a targeted therapy for the treatment of specific types of leukemia. Currently, the price in the domestic market is approximately 30,00···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 184
Gilteritinib is an FLT3 inhibitor targeting specific gene mutations, primarily used to treat relapsed or refractory acute myeloid leukemia (AML). Its ···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 196
Asteras Pharmaceuticals recently announced that the National Medical Products Administration (NMPA) of China has conditionally approved XOSPATA® (gite···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 190
Japanese pharmaceutical company Astellas recently announced that the NMPA of China has accepted its New Drug Application (NDA) for the targeted antica···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 185
The U.S. Food and Drug Administration (FDA) today approved Xospata (gilteritinib) tablets for the treatment of adult patients with relapsed or refract···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 180
If you accidentally ingest more than the dose prescribed by your doctor, contact them immediately. You may need to be hospitalized for observation and···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 194
Treatment with this product should continue until the patient no longer experiences clinical benefit or develops unacceptable toxicity. Because clinic···【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 186
The medicine can be taken before or after meals. It should be swallowed whole with water and should not be broken or crushed.【Read More】
Update: 2026-03-11Source: Haiou HealthViews: 164
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos